Sunday, January 09, 2022 5:51:16 PM
C-20. The world in which CYDY exists has NOW become a “PROVE IT WORLD”.
NADER HAS USED TWO LIFETIMES OF CEO CREDIBILITY with his nefarious shenanigans.
Nader has failed at an HIV submission, on purpose, leading to RTF; failed at 3 CoVID trial; and it looks like he failed the NASH trial as well.
So many missed deadlines, spin and lies, Nothing short of APPROVAL WILL SAVE THIS COMPANY now. But there is no time.
I invested because some really smart scientific folks believed in the LL MOA. “ Believe in the Science “ means that the drug meets the rigors of the scientific method. To date, LL has NOT achieved success in that arena, save for the HIV combo trial.
It doesn’t matter what is believed, it only matters what can be proved.
Nader is an absolute idiot who has inserted himself into trials he clearly knows nothing about.
In the last 3 years Nader has wasted over $300 with NOTHING TO SHOW FOR IT and expanded the authorized shares by almost 43% ( 300million shares) and has taken on crushing toxic debt.
There are no catalysts on the horizon and no money to satisfy debts and run rate for any significant amount of time at $.72 per share.
There are no reruns here, the company is IN WAY WORSE shape then the last time the SP was at these prices. Nader is no longer and “ unknown quantity” , he is NOW KNOWN TO BE:
1. A CROOK, STEALING SHARES IN UNMITIGATED GREED
2. A saboteur of his own BLA submission ( Amarex letter)
3. Liar ( see FDA BOMBSHELL public rebuke of Nader and the company) and many more false statements
4. Inside trader and stock manipulator
5. UNDER INVESTIGATION BY THE DOJ AND SEC.
NADER IS NOT Lassie…this is not a fairy tale…this is a nightmare.
NADER HAS USED TWO LIFETIMES OF CEO CREDIBILITY with his nefarious shenanigans.
Nader has failed at an HIV submission, on purpose, leading to RTF; failed at 3 CoVID trial; and it looks like he failed the NASH trial as well.
So many missed deadlines, spin and lies, Nothing short of APPROVAL WILL SAVE THIS COMPANY now. But there is no time.
I invested because some really smart scientific folks believed in the LL MOA. “ Believe in the Science “ means that the drug meets the rigors of the scientific method. To date, LL has NOT achieved success in that arena, save for the HIV combo trial.
It doesn’t matter what is believed, it only matters what can be proved.
Nader is an absolute idiot who has inserted himself into trials he clearly knows nothing about.
In the last 3 years Nader has wasted over $300 with NOTHING TO SHOW FOR IT and expanded the authorized shares by almost 43% ( 300million shares) and has taken on crushing toxic debt.
There are no catalysts on the horizon and no money to satisfy debts and run rate for any significant amount of time at $.72 per share.
There are no reruns here, the company is IN WAY WORSE shape then the last time the SP was at these prices. Nader is no longer and “ unknown quantity” , he is NOW KNOWN TO BE:
1. A CROOK, STEALING SHARES IN UNMITIGATED GREED
2. A saboteur of his own BLA submission ( Amarex letter)
3. Liar ( see FDA BOMBSHELL public rebuke of Nader and the company) and many more false statements
4. Inside trader and stock manipulator
5. UNDER INVESTIGATION BY THE DOJ AND SEC.
NADER IS NOT Lassie…this is not a fairy tale…this is a nightmare.
3X
God Bless America!
Recent CYDY News
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
